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ABSTRACT
Introduction Approximately 38% of haemodialysis 
patients carry Staphylococcus aureus in their noses, and 
carriers have a nearly four- fold increased risk of S. aureus 
access- related bloodstream infections (BSIs) compared 
with non- carriers. Our objective is to determine the 
clinical efficacy and effectiveness of a novel intervention 
using nasal povidone- iodine (PVI) to prevent BSIs among 
patients in haemodialysis units. We will survey patients 
and conduct qualitative interviews with healthcare workers 
to identify barriers and facilitators to implementing the 
intervention.
Methods and analysis We will perform an open- label, 
stepped- wedge cluster randomised trial to assess the 
effectiveness of nasal PVI compared with standard care. 
Sixteen outpatient haemodialysis units will participate 
in the study. The 3- year trial period will be divided into a 
4- month baseline period and eight additional 4- month time 
blocks. The primary outcome of the study will be S. aureus 
BSI, defined as a S. aureus positive blood culture collected 
in the outpatient setting or within one calendar day 
after a hospital admission. The study team will evaluate 
characteristics of individual patients and the clusters 
by exposure status (control or intervention) to assess 
the balance between groups, and calculate descriptive 
statistics such as average responses separately for control 
and intervention survey questions.
Ethics and dissemination This study has received IRB 
approval from all study sites. A Data Safety and Monitoring 
Board will monitor this multicentre clinical trial. We will 
present our results at international meetings. The study 
team will publish findings in peer- reviewed journals and 
make each accepted peer- reviewed manuscript publicly 
available.
Trial registration number NCT04210505.
INTRODUCTION
Patients on chronic haemodialysis are an ideal 
target population in whom to implement 
interventions to decrease rates of Staphylococcus 
aureus infections. More than 400 000 patients 
received haemodialysis in 2018, and the majority 
of these patients received in- centre haemodial-
ysis.1 Between 2005 and 2008, 43% of patients 
on haemodialysis tracked in the US Renal Data 
System were hospitalised for infection- related 
diagnoses.2 Approximately 30% of bloodstream 
infections (BSIs) among patients on haemodial-
ysis are caused by S. aureus3 4 and these infections 
cause considerable morbidity5–8 and mortality.7 9
Several factors increase the risk for S. aureus 
infections among patients on haemodialysis. 
First, a substantial proportion (38%) of these 
patients carry S. aureus in their noses, and 
carriers have a nearly four- fold increased risk 
of S. aureus access- related BSI compared with 
non- carriers.10 Second, these patients have 
impaired immune function, which makes 
them more susceptible to infection.11 Third, 
S. aureus can colonise the skin on patients’ 
vascular access sites (arteriovenous grafts or 
fistulae) and this organism can be introduced 
Strengths and limitations of this study
 ► Novel intervention targets a modifiable risk factor 
for Staphylococcus aureus bloodstream infections in 
patients on haemodialysis.
 ► Stepped- wedge cluster randomised trial design al-
lows units to serve as their own controls and as a 
control for other units, thus limiting selection bias 
and imbalance among the intervention and control 
units.
 ► Nasal povidone- iodine suppresses bacteria for only 
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into bloodstream when the skin is punctured or dialysis 
catheters are accessed.12–15 Fourth, the S. aureus colo-
nising one patient can be transmitted to other patients 
in the same haemodialysis unit. We previously found that 
87% of patients on dialysis who carried S. aureus in their 
noses and on their hands carried the same strains at both 
sites, suggesting transmission from the patients’ noses 
to their skin.16 The S. aureus strains can then be trans-
mitted from patient- to- patient in a haemodialysis unit via 
direct contact between patients and healthcare workers’ 
(HCWs) hands and indirectly by contaminated furniture 
and equipment.17 Unlike many other risk factors for BSI 
in this patient population (eg, comorbidities), S. aureus 
nasal carriage is modifiable and thus our intervention 
could substantially benefit this population.2 3 18
To date, studies that evaluated nasal decolonisation of 
patients on haemodialysis assessed the efficacy of intra-
nasal mupirocin ointment for decolonisation and infec-
tion prevention.19 However, few dialysis centres have 
included mupirocin decolonisation as a standard prac-
tice due to implementation barriers such as concern for 
mupirocin resistance and complicated protocols.19–22 
Povidone- iodine (PVI) has been used as an antiseptic in 
the healthcare setting for decades and PVI resistance has 
not been found.23 24 Thus, nasal PVI can be given to all 
patients who are not allergic to iodine regardless of their 
colonisation status. 5% PVI (w/w (0.5% available iodine) 
USP) is available under the US Food and Drug Adminis-
tration (FDA) Final Rule.25 Our objective is to perform 
a multicentre stepped- wedge cluster randomised trial 
(CRT) to determine the clinical efficacy and effectiveness 
of a novel intervention using nasal PVI to prevent BSIs 
among patients on hamodialysis. We will survey patients 
and conduct qualitative interviews with HCWs to identify 
barriers and facilitators to implementing the intervention.
Objective 1
Conduct a multicentre, stepped- wedge CRT to determine 
whether nasal PVI decolonisation reduces infections 
among patients on haemodialysis.
Objective 2
Survey patients to assess their satisfaction with nasal PVI 
decolonisation, assess PVI’s role in patient activation 
around their own health before and after PVI use, and 
identify barriers and facilitators to implementation.
Objective 3
Examine HCW satisfaction with implementation of nasal 
PVI decolonisation and assess barriers and facilitators to 
the process via qualitative interviews and site visits.
METHODS AND ANALYSIS
Study design
We will perform an open- label, stepped- wedge CRT to 
assess the effectiveness of nasal PVI compared with stan-
dard care. Our objectives are to evaluate whether using 
intranasal PVI will reduce rates of S. aureus BSI among 
patients on haemodialysis, to qualitatively evaluate the 
implementation of this intervention, and to measure 
HCW and patient satisfaction with PVI. We will randomly 
assign when haemodialysis units (clusters) will cross over 
from the control group to the intervention group such 
that all units will eventually receive the intervention.26 
The control group will consist of standard care as regu-
lated by US Centers for Medicare and Medicaid Services 
(CMS). We will include new patients who begin haemo-
dialysis and stop patient follow- up when a patient is no 
longer on haemodialysis (eg, recovery of kidney function, 
kidney transplantation or death).2
Sixteen outpatient haemodialysis units will participate 
in the study. The 3- year trial period will be divided into 
a 4- month baseline period and eight additional 4- month 
time blocks (table 1). All units will begin in the control 
condition (C; no intervention). Two units (a unit pair) 
will be added to the intervention (I) in a stepwise fashion 
at the beginning of the eight additional time blocks.26
Study setting and participants
The proposed research will be performed at outpatient 
haemodialysis units affiliated with five US academic 
medical centres in the Southeast, Midwest and Northeast. 
This multicentre study of geographically diverse hospital 
systems and their patient populations will improve the 
external validity of our study. We have confirmed that none 
of the study sites currently perform nasal decolonisation.
We will enrol patients if they are 18 years or older 
and receiving outpatient chronic haemodialysis (three 
sessions a week). We will exclude patients receiving 
peritoneal dialysis or home haemodialysis, patients with 
documented or verbalised sensitivity or allergy to iodine 
or iodine- based contrast, patients with known pregnancy, 
and patients on treatment for bacterial infection. We will 
enroll adult HCWs working at any of the 16 haemodialysis 
units who are willing to participate in the semistructured 
interviews.
Screening and recruitment
Research team members at each dialysis centre will 
identify patients that meet inclusion criteria and will 
discuss the study with patients during a haemodialysis 
session, while ensuring that patient care is not delayed or 
disrupted. This study was approved with a waiver of signed 
consent, as the study is deemed low- risk and patients may 
have trouble writing while receiving haemodialysis. Thus, 
patients who verbally agree to the informed consent will 
be included in the study.
Two research team anthropologists will schedule and 
conduct semistructured interviews with 5–10 HCW at haemo-
dialysis units across the five centres to examine the contextual 
factors that influence adoption of nasal PVI decolonisation. 
The anthropologists will ask each unit’s medical director for 
permission to interview staff and for the names of potential 
interviewees. The anthropologists will invite potential inter-
viewees—the nurse manager, a physician, nurses, nursing 
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This study has received institutional IRB approval from the 
University of Iowa and site- specific IRB approval, including 
waiver of documentation of informed consent. We will 
offer participants the opportunity to talk with the treating 
physician or their family member before consenting. Study 
participation will not influence the standard of care subjects 
would otherwise receive for their disease process. To mini-
mise risks, all subjects will be carefully prescreened to iden-
tify any factors that could contribute to increased risk. We 
will capture adherence to the intervention during repeated 
site visits and patient surveys administered throughout the 
intervention period, and we will record patient drop- out. We 
will store all confidential information in locked offices and 
store electronic data on password- protected computers only 
available to study team members. Participants will receive 
study team members’ contact information.
Sample size and power
We used the method described by Hussey and Hughes 
to calculate the sample size and the study’s power.27 As 
described above, the stepped- wedge study will last 36 
months (time points) with data collected monthly from 
16 sites (clusters). After the baseline period, two sites 
will transition to the intervention at the start of each 
subsequent 4- month block. Our pilot data suggested 
that approximately 1825 patients will receive haemodial-
ysis at any given time across all sites, with approximately 
100 patients per site per time point (N). We estimated 
the between site variability as τ2=0.01. Given that 3% of 
patients who received haemodialysis at our study sites 
during 2016 acquired S. aureus BSI, we estimated the 
within- site variability to be 0.00029. Thus, we estimated 
that we will have 98% power to see a change in the rate 
of S. aureus BSI from 3% to 2% (absolute difference=1%, 
OR=0.66). This difference is more conservative than the 
difference seen in prior mupirocin decolonisation studies 
among patients on haemodialysis (OR=0.32–0.51).19 Our 
pilot data indicated that 30% of patients on haemodialysis 
at our study sites were dialyzed through central venous 
catheters, 5% of whom acquired S. aureus BSI in 2016. 
Given this information, we estimated that a subset anal-
ysis of patients dialyzed through catheters will have 99% 
power to identify a decrease in infections from 5% to 2% 
(absolute difference=3%, OR=0.40).
Randomisation
We paired dialysis units into 2- unit blocks according to 
two rules: (1) The dialysis units in a pair were not within 
the same geographical region and (2) The approximate 
total monthly unique patients in a given unit block would 
be approximately 150 patients. Two study team members 
independently created the dialysis unit blocks and they 
minimised the variation from the ideal unit block size 
when their pairings disagreed. After we created the 
two- unit block pairs, we used the sample function in R 
without replacement to randomise the order in which the 
pairs would enter the intervention phase. Each unit block 
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randomisation in a password- protected file. Only the two 
team members who performed the randomisation and 
3M, which must coordinate delivery of the product to the 
participating sites in accordance with the project timeline, 
have access to that file. We will notify sites 4 months before 
their planned intervention start date. The research team 
is well connected with all sites and will prevent premature 
implementation of the intervention.
Intervention
Events and procedures for haemodialysis subjects will 
occur over four research visits (table 2). Research 
personnel will visit the dialysis centres four times over the 
study period.
Visit 1
Approximately a month before a dialysis unit is scheduled 
to begin the intervention, a study team member will visit 
the dialysis unit. During the visit, the study team member 
will describe the study, obtain verbal informed consent 
from patients present, and administer the preinterven-
tion (control) survey to all patients on haemodialysis who 
agree to participate. A study team member also will swab 
participants’ noses to identify patients who carry S. aureus 
at baseline.
Visit 2
When a dialysis unit is scheduled to begin the interven-
tion, study personnel will obtain verbal informed consent 
from patients present and give each participating patient 
their first disposable, single- use bottles of PVI, 4 appli-
cators and illustrated instructions for use. Participating 
patients will apply PVI at each haemodialysis appoint-
ment. Patients will be encouraged to apply the PVI to 
their own noses, but they can also ask a nurse or techni-
cian for assistance. Patients will also have the option to 
apply PVI at home.
Visit 3
After a dialysis session has begun and after obtaining 
verbal informed consent from the patient, a study team 
member will administer the first intervention survey to the 
patient. This intervention survey will assess acceptability 
of PVI approximately 1 month after the intervention has 
started.
Visit 4
Approximately 5 months after the beginning of the inter-
vention and after obtaining verbal informed consent 
from the patient, a study team member will administer 
the second intervention survey. The two intervention 
surveys will ask the same questions and will be performed 
in the same manner. The results of the control period 
survey and the two intervention period surveys for each 
patient can be linked together.
Staphylococcus aureus point prevalence studies
Each haemodialysis unit will collect nasal swabs from 
each participating haemodialysis patient’s nose during 
the baseline period and twice per year over the 3- year 
study period (total of six times including baseline) we will 
collect nasal swabs to determine S. aureus colonisation 
status.
HCW interview
Two members of the research team will conduct semistruc-
tured in- person interviews with staff during site visits. The 
semistructured interviews will include open- ended ques-
tions to explore domains including barriers and facilitators 
to implementing the intervention, provider and patient 
compliance with PVI decolonisation, and the acceptability 
and feasibility of PVI decolonisation. Interviews will be 
audiorecorded with the HCWs’ permission and transcribed.
Outcomes and data collection
Primary outcome
The primary outcome of the study will be S. aureus BSI, 
defined as a S. aureus positive blood culture collected in 
the outpatient setting or within one calendar day after 
a hospital admission. This outcome is collected every 
month by dialysis staff or infection prevention staff at 
each hospital system in accordance with The US Centers 
for Disease Control and Prevention’s National Healthcare 
Safety Network and the US CMS requirements. These 
data will be shared with the study team and validated via 
chart review.
Table 2 Schedule of events table for both haemodialysis and healthcare worker visits





Review of inclusion/exclusion criteria and lab results to 
confirm subject eligibility
X X           
Testing for Staphylococcus aureus nasal carriage X         X   
Preintervention Survey X             
Povidone- iodine administration   X     X     
Intervention Survey     X X       
Healthcare worker interview             X
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Secondary and additional outcomes
Definitions of secondary outcomes are presented in 
table 3 with additional evaluated outcomes presented in 
table 4.
During each site’s intervention period, a member of 
the study team will swab each participant’s nares during 
their haemodialysis session after the patient applies PVI 
to determine if patients are colonised with S. aureus after 
applying PVI and during the at- risk period. S. aureus 
isolates will be tested for methicillin- susceptibility and 
the research team will perform pulsed field gel elec-
trophoresis on all nasal isolates and if available, blood-
stream isolates to assess whether serial isolates from the 
same patient are related, whether isolates from different 
patients in the same dialysis unit are related, and whether 
nasal isolates and infecting isolates from the same patient 
are identical. A sample of S. aureus isolates will be evalu-
ated using whole genome sequencing. Laboratory testing 
will occur in a single laboratory using standardised 
methodology.
Statistical and ethnographic analysis
Objective 1
The study team will evaluate characteristics of individual 
patients and the clusters by exposure status (control or 
intervention) to assess the balance between groups. As 
most participants will take part in both settings, paired 
t- tests, McNemar’s test and repeated measures analysis of 
variance will be used as appropriate. The overall propor-
tion of unique patients in the control group who acquire 
infections compared with the intervention group will be 
assessed via McNemar’s Test.
In the primary analysis, the study team will use a gener-
alised linear mixed model (GLMM) with a logit link func-
tion to perform an analysis at the individual patient level 
evaluating the association between nasal PVI and S. aureus 
BSI. The model will include step and intervention indi-
cators as fixed effects and a random intercept for cluster 
to account for hospital dependence. The study team will 
statistically adjust for important confounding variables, 
such as dialysis access type. The study team will perform an 
intention- to- treat analysis, assuming all patients received 
nasal PVI during the intervention periods. Patients who 
stop using PVI will be included in the study and evaluated 
for outcomes in this intention- to- treat analysis. Reasons 
for study ‘drop- out’ such as death or renal transplant are 
not related to the intervention. However, the study team 
will model time to drop- out to characterise this patient 
population. An analysis will also be performed among 
patients who met the inclusion criteria, agreed to partic-
ipate in the study, and received at least one dose of PVI.
Because patients who receive haemodialysis through 
central venous catheters are at the highest risk of infec-
tion, the study team use the GLMM methods described 
above to evaluate the association between nasal PVI and 
S. aureus BSI stratified by dialysis access type. The study 
team will also perform exploratory analyses to assess 
the effect of rural vs urban haemodialysis units and the 
effect of nasal PVI on methicillin- resistant S. aureus and 
Table 3 Definitions of secondary outcomes (CDC NHSN definitions)
Bloodstream infection (BSI)
A positive blood specimen collected in the outpatient setting or within one 
calendar day after a hospital admission.
Access related bloodstream infection (ARBSI) A bloodstream infection with the suspected source reported as the vascular 
access or uncertain.
Staphylococcus aureus ARBSI An ARBSI in which the blood specimen was determined to be S. aureus.
Local access site infection Pus, redness or increased swelling at the vascular access site when an ARBSI 
is not present.
S aureus local access site infection Pus, redness or increased swelling at the vascular access site when an ARBSI 
is not present but with positive culture for S. aureus.
S aureus BSI among intervention participants An S. aureus positive blood specimen collected in the outpatient setting or 
within one calendar day after a hospital admission from patients participating 
in the intervention.
CDC NHSN, Centres for Disease Control and Prevention’s National Healthcare Safety Network.
Table 4 Additional outcomes evaluated
Patient satisfaction with nasal PVI
Barriers and facilitators to the intervention collected from patients through 
qualitative surveys.
Healthcare worker satisfaction with intervention Barriers and facilitators to the intervention collected through qualitative 
interviews with healthcare workers.
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methicillin- susceptible S. aureus BSIs separately. Finally, 
the study team will evaluate the effect of nasal PVI on the 
secondary outcomes: all BSI caused by any pathogen, all 
BSI caused by any pathogen, local access site infection 
and vascular access infection. The study team will use SAS 
V.9.4 for all analyses.
Objective 2
The study team will calculate descriptive statistics for 
control and intervention survey questions. They will use 
a two- sample Fisher’s exact test to assess differences in 
the patients’ responses to specific questions during the 
control and intervention periods. The study team will use 
bivariable and multivariate regression analysis to explore 
associations between survey measures and covariates.
Objective 3
Investigators will read a subset of transcripts and generate 
a preliminary codebook using an integrated approach to 
thematic analysis that includes a priori project- specific 
thematic codes, Consolidated Framework for Implemen-
tation Research constructs and inductive codes identified 
during team discussions. Thereafter, the team will code 
documents, then iteratively adapt the codebook, conduct 
preliminary analyses, adapt the interview guide if needed 
and gauge whether data saturation (ie, no new themes or 
patterns emerge) has been reached. If data saturation has 
not been attained or if new areas are identified, we will 
perform, record and analyse additional telephone inter-
views. The team will document codebook changes and 
the rationale for each change and will keep an audit trail.
Patient and public involvement
Neither patients nor members of the public participated 
in designing this study.
Ethics and dissemination
The risk to patients is low in this study; however, a data 
and safety monitoring board (DSMB) will oversee this 
study. The DSMB will be made up of clinical, biostatis-
tical, infectious disease and renal disease experts who 
are approved by the Agency for Health Research and 
Quality. Occurrence of adverse events will be monitored 
throughout the trial by surveys and the study team, and 
will cover all randomised subjects. Rare allergy to PVI will 
be treated by haemodialysis staff if needed. This is a phase 
IV study of an antiseptic that is available under the FDA 
Final Rule (Federal Register December 20, 2017).25 Any 
potential side effects from PVI will be captured through 
patient surveys. To protect confidentiality, we will assign 
each subject a study ID. All electronic files are stored on 
password- protected computers that are connected to a 
secured shared drive. Nasal swabs will be labelled with 
a coding descriptor, and no PHI will be collected from 
the lab. The isolates will be discarded after the results 
are finalised. Only the PI, data analysts, statistician and 
the DSMB will have access to the final trial data set. Site 
principal investigators will have direct access to their own 
site’s data sets, and will have access to other sites’ data by 
request. In year 5 of the study, we will present our results 
at international meetings. We will publish our findings 
in peer- reviewed journals and make each peer- reviewed 
accepted manuscript publicly available.
DISCUSSION
Prior studies have found that nasal decolonisation with 
mupirocin reduced infection rates among patients on 
haemodialysis.13 16 19 For example, Weiner et al demon-
strated that nasal mupirocin was associated with a 
fourfold reduction in S. aureus BSIs in this patient popu-
lation.28 However, consistent use of mupirocin can lead 
to mupirocin- resistant S. aureus.13 A meta- analysis found 
that decolonisation with mupirocin was associated with 
a 59% reduction in S. aureus infections among dialysis 
patients, but up to 10% of patients who used mupirocin 
become colonised with a mupirocin- resistant S. aureus 
strain.19 Given that mupirocin prophylaxis can increase 
the frequency of mupirocin- resistant S. aureus isolates, 
and that the mupirocin decolonisation protocol is often 
difficult to implement, most haemodialysis units do not 
routinely decolonise patients with mupirocin.19
Nasal PVI may be preferred over mupirocin for long- 
term prevention of S. aureus infections because it is easy to 
use and it has multiple targets of action—thus, the risk of 
PVI resistance among S. aureus isolates is minimal.23 29–31 
PVI has been used in healthcare for years for skin anti-
sepsis. Recently, small, single- centre studies found that 
nasal PVI was associated with decreased surgical site 
infection rates, and that surgical patients preferred this 
product over mupirocin because it had fewer side effects 
and was more pleasant.32–35 Some investigators have used 
PVI at haemodialysis catheter exit sites or for catheter 
care.36 37 However, no published studies have evaluated 
nasal PVI for decolonising patients on haemodialysis.
Our objectives are to evaluate whether decolonising 
patients’ noses with PVI will reduce rates of S. aureus BSI 
among patients on haemodialysis, to qualitatively evaluate 
the implementation of this intervention, and to assess 
patient and HCW satisfaction with PVI. This trial will 
be performed at 16 outpatient haemodialysis units affil-
iated with five academic medical centres. These ambu-
latory haemodialysis units are geographically dispersed 
and care for both rural and urban patients who receive 
chronic care.
We chose the stepped- wedge CRT design for multiple 
reasons. First, since nasal PVI could prevent endogenous 
S. aureus infection and could prevent exogenous transmis-
sion of this organism from patient to patient, individual 
randomisation would not allow us to adequately assess the 
full effect of this intervention. Second, units will serve as 
their own controls and as controls for other units, thus 
limiting selection bias and imbalance among the inter-
vention and control units.26 Third, the staggered starting 
dates can help us measure and adjust for temporal biases 
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Limitations
The proposed study has three main limitations. First, 
nasal PVI suppresses bacteria for only 12–24 hours.31 
Thus, PVI must be reapplied before each procedure. 
Second, we will not compare PVI with mupirocin. 
Instead, our control group will be standard care, which 
is justified because mupirocin has not been routinely 
used for preventing BSI among patients on haemodialysis 
due to implementation barriers. Third, PVI is considered 
a novel intervention for patients on haemodialysis, and 
thus, we are required to obtain informed consent from 
each patient. Therefore, patients who do not consent to 
using nasal PVI could transmit S. aureus to patients who 
do participate in the intervention.
Significance
Nasal PVI is currently used in many hospitals to prevent 
surgical site infections. Our study evaluates this product 
in a new patient population. This large stepped- wedge 
CRT aims to determine whether nasal PVI decreases rates 
of S. aureus BSI among patients on haemodialysis, and 
to collect data on barriers and facilitators to implemen-
tation. Given that PVI as widely available and inexpen-
sive, is easy to use and implement, and does not cause 
resistance, this intervention could be more generalisable 
than mupirocin ointment. An effective intervention to 
prevent infections among patients on haemodialysis 
could improve outcomes among the 2 million people who 
receive renal replacement therapy worldwide.38
Trial status
Trial is currently ongoing.
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